Germany Losing Pharmaceutical Innovation to USA Due to Health Reform

Germany is reportedly losing a significant portion of newly approved drugs to the USA, with pharmaceutical companies preferring to launch new therapies there due to the financial impact of health reforms in Germany.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

fazGerman2d ago

Innovationsrückstand: Warum Deutschland jedes dritte neu zugelassene Arzneimittel an die USA verliert

Herstellerabschlag rauf, Rabattverträge rein: Die Gesundheitsreform kostet die Pharmaindustrie Milliarden. Dabei gehen Studien zurück – und neue Therapien beginnen deutsche Unternehmen eher in den USA als in Europa.

Read full article →

PERSPECTA

PERSPECTA

Germany Losing Pharmaceutical Innovation to USA Due to Health Reform

Sources

Innovationsrückstand: Warum Deutschland jedes dritte neu zugelassene Arzneimittel an die USA verliert

Related Stories

At least four injured in incident at BP refinery near Seattle

The 'Superpower' of Short Sleepers: 1% of Population Needs Less Sleep Without Health Impact

Cosmetic Risks Rise: 30% Increase in Adverse Effect Notifications in Spain

Lagos NMA Chairman Removed, New Leader Elected Amid Constitutional Infractions

PERSPECTA